Dupilumab nonresponders in atopic dermatitis

It has been 5 years since dupilumab was approved by the US Food and Drug Administration for moderate to severe atopic dermatitis (AD). There are phase 3 studies and real-world data that have shown dupilumab is effective in most patients with AD, with a relatively safe profile. In a review of real-world data,1 the percentage of patients with AD who achieved EASI75 (ie, an improvement in eczema severity by 75% based on Eczema Area and Severity Index) is approximately 70% over a period of 40 weeks.